BioCentury | Oct 16, 2014
Distillery Therapeutics

Indication: Cancer

...Inc. has the g-secretase inhibitor FRM-0962 in Phase II testing to treat Alzheimer's disease (AD). Humanetics Corp....
BioCentury | Aug 19, 2013
Emerging Company Profile

PxRadia: Ceramide selectivity

...profile in humans. At least two companies are developing products to treat post-exposure GI ARS. Humanetics Corp....
...Radiobiology Research Institute (AFRRI), Bethesda, Md. Biomedical Advanced Research and Development Authority (BARDA), Washington, D.C. Humanetics Corp....
BioCentury | Jun 27, 2011
Company News

Humanetics other news

...HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Humanetics a two-year, $3.5 million contract for...
...topoisomerase II (TOP2) has completed a Phase I trial to treat acute radiation syndrome (ARS). Humanetics Corp....
BioCentury | Jul 20, 2009
Clinical News

NIC5-15: Phase IIa data

...of the trial. Data were presented at the International Conference on Alzheimer's Disease in Vienna. Humanetics Corp....
BioCentury | Mar 19, 2009
Distillery Therapeutics

Indication: Neurology

...and Elan Corp plc's g-secretase inhibitor LY450139 is in Phase III AD trials. NIC5-15 from Humanetics Corp....
BioCentury | Feb 26, 2009
Cover Story

Genentech's new parADigm

...MCH2) Genentech CASP6 inhibitor CASP6 inhibitor Discovery γ-Secretase Eli Lilly/Elan LY450139 γ-Secretase inhibitor Phase III Humanetics Corp....
BioCentury | Jul 31, 2008
Targets & Mechanisms

Cleaving Schizophrenia

...investigator on a Phase IIb AD trial of NIC5-15 , a selective g-secretase inhibitor from Humanetics Corp....
...Germany Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Humanetics Corp....
BioCentury | Jul 7, 2008
Strategy

Flurizan’s failure adds value

...modulating gamma secretase , although the direct mechanism is unknown. Eli Lilly and Co. and Humanetics Corp....
...inhibitors in development to treat AD. Lilly’s LY450139 began Phase III testing in March, and Humanetics’...
...Institutions Mentioned Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Humanetics Corp....
BioCentury | Feb 21, 2008
Cover Story

Exploiting a window into AD

...flurbiprofen, g-secretase modulator Phase III Eli Lilly and Co. (NYSE:LLY) LY450139 g-secretase inhibitor Phase II Humanetics Corp....
BioCentury | Jan 21, 2008
Clinical News

BIO 300: Phase I data

...trial evaluated single oral doses of 500, 1,000, 1,500 and 2,000 mg of BIO 300. Humanetics Corp....
Items per page:
1 - 10 of 19
BioCentury | Oct 16, 2014
Distillery Therapeutics

Indication: Cancer

...Inc. has the g-secretase inhibitor FRM-0962 in Phase II testing to treat Alzheimer's disease (AD). Humanetics Corp....
BioCentury | Aug 19, 2013
Emerging Company Profile

PxRadia: Ceramide selectivity

...profile in humans. At least two companies are developing products to treat post-exposure GI ARS. Humanetics Corp....
...Radiobiology Research Institute (AFRRI), Bethesda, Md. Biomedical Advanced Research and Development Authority (BARDA), Washington, D.C. Humanetics Corp....
BioCentury | Jun 27, 2011
Company News

Humanetics other news

...HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Humanetics a two-year, $3.5 million contract for...
...topoisomerase II (TOP2) has completed a Phase I trial to treat acute radiation syndrome (ARS). Humanetics Corp....
BioCentury | Jul 20, 2009
Clinical News

NIC5-15: Phase IIa data

...of the trial. Data were presented at the International Conference on Alzheimer's Disease in Vienna. Humanetics Corp....
BioCentury | Mar 19, 2009
Distillery Therapeutics

Indication: Neurology

...and Elan Corp plc's g-secretase inhibitor LY450139 is in Phase III AD trials. NIC5-15 from Humanetics Corp....
BioCentury | Feb 26, 2009
Cover Story

Genentech's new parADigm

...MCH2) Genentech CASP6 inhibitor CASP6 inhibitor Discovery γ-Secretase Eli Lilly/Elan LY450139 γ-Secretase inhibitor Phase III Humanetics Corp....
BioCentury | Jul 31, 2008
Targets & Mechanisms

Cleaving Schizophrenia

...investigator on a Phase IIb AD trial of NIC5-15 , a selective g-secretase inhibitor from Humanetics Corp....
...Germany Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Humanetics Corp....
BioCentury | Jul 7, 2008
Strategy

Flurizan’s failure adds value

...modulating gamma secretase , although the direct mechanism is unknown. Eli Lilly and Co. and Humanetics Corp....
...inhibitors in development to treat AD. Lilly’s LY450139 began Phase III testing in March, and Humanetics’...
...Institutions Mentioned Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Humanetics Corp....
BioCentury | Feb 21, 2008
Cover Story

Exploiting a window into AD

...flurbiprofen, g-secretase modulator Phase III Eli Lilly and Co. (NYSE:LLY) LY450139 g-secretase inhibitor Phase II Humanetics Corp....
BioCentury | Jan 21, 2008
Clinical News

BIO 300: Phase I data

...trial evaluated single oral doses of 500, 1,000, 1,500 and 2,000 mg of BIO 300. Humanetics Corp....
Items per page:
1 - 10 of 19